Berstein analyst Ronny Gal told investors that Jazz Pharmaceutical’s move could open the door for other pharmaceutical companies to patent similar DDIs and keep generics at bay, reports RAPS.
“What Jazz did with Xyrem was to study in details the drug-drug interaction of its drug, patent that knowledge and then add specific language to its label addressing the issue,” Gal explained.
